Ron Leuty
@rleutybiotech.bsky.social
Biotech reporter, San Francisco Business Times
Curve Bio is first new biotech tenant in Longfellow's conversion project, the San Mateo Science Center - San Francisco Business Times www.bizjournals.com/sanfrancisco...
Peninsula project lands first new tenant more than four years after launching a conversion to biotech - San Francisco Business Times
Converted for biotech, Peninsula project lands 1st life sciences tenant years later
www.bizjournals.com
December 1, 2025 at 11:23 PM
Curve Bio is first new biotech tenant in Longfellow's conversion project, the San Mateo Science Center - San Francisco Business Times www.bizjournals.com/sanfrancisco...
ICYMI: Gilead Sciences is looking at a potential 800,000-square-foot expansion at its HQ campus - San Francisco Business Times www.bizjournals.com/sanfrancisco...
Gilead Sciences is planning an 800,000 square foot expansion at its Foster City headquarters - San Francisco Business Times
Buildup: Inside Gilead's plans for 800K square feet in Foster City
www.bizjournals.com
December 1, 2025 at 3:54 PM
ICYMI: Gilead Sciences is looking at a potential 800,000-square-foot expansion at its HQ campus - San Francisco Business Times www.bizjournals.com/sanfrancisco...
How Twist Bio brought its team into one space with help of a renter's market www.bizjournals.com/sanfrancisco...
A 'renter’s market' allowed this CEO to bring everyone together for less - San Francisco Business Times
How this biotech company plans to bring its team together for less
www.bizjournals.com
December 1, 2025 at 3:52 PM
How Twist Bio brought its team into one space with help of a renter's market www.bizjournals.com/sanfrancisco...
Quest Diagnostics inks deal to supply Octave Bioscience's MS test - San Francisco Business Times www.bizjournals.com/sanfrancisco...
Octave Bio lands massive deal with Quest Diagnostics that will expand reach of its multiple sclerosis tests - San Francisco Business Times
Octave Bio lands massive deal with Quest Diagnostics that will expand reach of its multiple sclerosis tests
www.bizjournals.com
December 1, 2025 at 3:48 PM
Quest Diagnostics inks deal to supply Octave Bioscience's MS test - San Francisco Business Times www.bizjournals.com/sanfrancisco...
Gilead Sciences targets 800,000-square-foot expansion at HQ campus - San Francisco Business Times www.bizjournals.com/sanfrancisco...
Gilead Sciences is planning an 800,000 square foot expansion at its Foster City headquarters - San Francisco Business Times
Buildup: Inside Gilead's plans for 800K square feet in Foster City
www.bizjournals.com
November 27, 2025 at 5:47 PM
Gilead Sciences targets 800,000-square-foot expansion at HQ campus - San Francisco Business Times www.bizjournals.com/sanfrancisco...
How this Bay Area biotech pivoted, is hiring and is 'almost to the starting line' - San Francisco Business Times www.bizjournals.com/sanfrancisco...
After pivot, this Bay Area CEO says company is hiring and 'almost to the starting line' - San Francisco Business Times
"A drug that stops kidney function decline is transformative," Vera Therapeutics founder and CEO Marshall Fordyce said.
www.bizjournals.com
November 26, 2025 at 5:40 PM
How this Bay Area biotech pivoted, is hiring and is 'almost to the starting line' - San Francisco Business Times www.bizjournals.com/sanfrancisco...
Berkeley and Emeryville built for biotech just before the sector crashed — what happens with those vacant buildings now? - San Francisco Business Times www.bizjournals.com/sanfrancisco...
Berkeley and Emeryville built for biotech just before the sector crashed — what happens with those vacant buildings now? - San Francisco Business Times
In a sign of trouble for the East Bay's life sciences cluster, Oxford Properties is selling its Emeryville site after abandoning lab development plans. Here's how that makes for part of the bigger pic...
www.bizjournals.com
November 21, 2025 at 4:54 PM
Berkeley and Emeryville built for biotech just before the sector crashed — what happens with those vacant buildings now? - San Francisco Business Times www.bizjournals.com/sanfrancisco...
Abbott Laboratories and Cologuard maker Exact Sciences land $23 billion deal — Here's how Bay Area could be affected www.bizjournals.com/sanfrancisco...
Abbott Laboratories and Cologuard maker Exact Sciences land $23 billion deal — Here's how Bay Area could be affected - San Francisco Business Times
Why Abbott Labs is making a big buy with potential Bay Area impact
www.bizjournals.com
November 20, 2025 at 8:01 PM
Abbott Laboratories and Cologuard maker Exact Sciences land $23 billion deal — Here's how Bay Area could be affected www.bizjournals.com/sanfrancisco...
Profluent, which just raised $106M from Jeff Bezos and others, launched a partnership with the Rett Syndrome Research Trust that focuses on base editors to permanently correct mutations to the gene that cause the rare neurodevelopment disorder www.bizjournals.com/sanfrancisco...
East Bay AI biotech company raises $106 million from Jeff Bezos and others - San Francisco Business Times
Created by leaders of a Salesforce skunkworks, this East Bay AI company just raised $106 million from Jeff Bezos and others.
www.bizjournals.com
November 19, 2025 at 10:01 PM
Profluent, which just raised $106M from Jeff Bezos and others, launched a partnership with the Rett Syndrome Research Trust that focuses on base editors to permanently correct mutations to the gene that cause the rare neurodevelopment disorder www.bizjournals.com/sanfrancisco...
In big win for Freenome's CEO in his 1st year, cancer test company inks deal with Roche - San Francisco Business Times www.bizjournals.com/sanfrancisco...
Freenome lands global commercialization deal with Roche for blood-based colon cancer test - San Francisco Business Times
Brisbane-based Freenome has locked in a second major partnership for its blood-based cancer screening test, this time with a Switzerland-based diagnostics giant that already has invested hundreds of m...
www.bizjournals.com
November 18, 2025 at 11:59 PM
In big win for Freenome's CEO in his 1st year, cancer test company inks deal with Roche - San Francisco Business Times www.bizjournals.com/sanfrancisco...
Former Amgen site head joins Genentech as former Genentech cancer immunology exec moves to Amgen
www.bizjournals.com/sanfrancisco...
www.bizjournals.com/sanfrancisco...
Former Amgen site head joins Genentech as former Genentech cancer immunology exec moves to Amgen - San Francisco Business Times
Two big biotech companies have traded top research executives. Learn who went where.
www.bizjournals.com
November 18, 2025 at 5:14 PM
Former Amgen site head joins Genentech as former Genentech cancer immunology exec moves to Amgen
www.bizjournals.com/sanfrancisco...
www.bizjournals.com/sanfrancisco...
Sutter Health will construct a 272-bed, eight-story medical center near Levi’s Stadium as part of the not-for-profit health care system's $2.8 billion buildout in the heart of Silicon Valley.
www.bizjournals.com/sanfrancisco...
www.bizjournals.com/sanfrancisco...
Sutter Health to build record-setting new hospital campus in Santa Clara - San Francisco Business Times
Sutter Health has earmarked its largest ever facilities investment with a major hospital project in Santa Clara.
www.bizjournals.com
November 18, 2025 at 1:01 AM
Sutter Health will construct a 272-bed, eight-story medical center near Levi’s Stadium as part of the not-for-profit health care system's $2.8 billion buildout in the heart of Silicon Valley.
www.bizjournals.com/sanfrancisco...
www.bizjournals.com/sanfrancisco...
Reposted by Ron Leuty
Scheduling mifepristone largely invalidates the point of the schedule.
Ostensibly, the schedule is meant to monitor drugs *which have the ability to form physical dependence*.
This step makes the schedule a list of drugs that lawmakers dislike for feelings reasons.
www.pbs.org/news-hour/sh...
Ostensibly, the schedule is meant to monitor drugs *which have the ability to form physical dependence*.
This step makes the schedule a list of drugs that lawmakers dislike for feelings reasons.
www.pbs.org/news-hour/sh...
Louisiana restricts access to abortion pills by classifying them as a controlled substance
A bill that would restrict access to abortion pills has been signed into law in Louisiana. The law reclassifies the drugs as a controlled substance, grouping them with Xanax and Valium. Possession wit...
www.pbs.org
November 17, 2025 at 5:11 PM
Scheduling mifepristone largely invalidates the point of the schedule.
Ostensibly, the schedule is meant to monitor drugs *which have the ability to form physical dependence*.
This step makes the schedule a list of drugs that lawmakers dislike for feelings reasons.
www.pbs.org/news-hour/sh...
Ostensibly, the schedule is meant to monitor drugs *which have the ability to form physical dependence*.
This step makes the schedule a list of drugs that lawmakers dislike for feelings reasons.
www.pbs.org/news-hour/sh...
Jeff Bluestone exits as Sonoma Bio CEO as Stephen Dilly steps in - San Francisco Business Times www.bizjournals.com/sanfrancisco...
Jeff Bluestone to step down as CEO of Sonoma Biotherapeutics - San Francisco Business Times
Biotech's co-founder won Nobel Prize. Now another is exiting CEO job
www.bizjournals.com
November 17, 2025 at 2:57 PM
Jeff Bluestone exits as Sonoma Bio CEO as Stephen Dilly steps in - San Francisco Business Times www.bizjournals.com/sanfrancisco...
Revolution Medicines is doing something truly revolutionary — it's hired hundreds just this year and it's still looking for more people
www.bizjournals.com/sanfrancisco...
www.bizjournals.com/sanfrancisco...
Revolution Medicine is 'within sight' of 1,000 employees and looking for a new office to fit them - San Francisco Business Times
"We're growing a lot. There's more growth ahead of us," says Revolution Medicines CEO Mark Goldsmith. Here's how his company is defying the biotech sector's pain.
www.bizjournals.com
November 17, 2025 at 2:52 PM
Revolution Medicines is doing something truly revolutionary — it's hired hundreds just this year and it's still looking for more people
www.bizjournals.com/sanfrancisco...
www.bizjournals.com/sanfrancisco...
AbbVie and Calico end 11-year partnership without approved drug - San Francisco Business Times www.bizjournals.com/sanfrancisco...
AbbVie and Calico end groundbreaking partnership after 11 years without an approved drug - San Francisco Business Times
An 11-year, $2 billion partnership has yet to produce an approved drug, but five attempts are in clinical trials.
www.bizjournals.com
November 13, 2025 at 4:29 PM
AbbVie and Calico end 11-year partnership without approved drug - San Francisco Business Times www.bizjournals.com/sanfrancisco...
Health care providers join suit alleging 'price-fixing' by 'cartel' of insurers for out-of-network work www.bizjournals.com/sanfrancisco...
California group joins massive suit alleging price fixing by 'mafia enforcer' for major insurers - San Francisco Business Times
The nation’s largest health insurance companies stand accused of conspiring to suppress reimbursement rates for hundreds of millions of medical procedures. They call it competition. Plaintiffs say it'...
www.bizjournals.com
November 13, 2025 at 4:25 PM
Health care providers join suit alleging 'price-fixing' by 'cartel' of insurers for out-of-network work www.bizjournals.com/sanfrancisco...
The nine-year-old company, which IPO'd in February 2024, peaked at 237 employees in spring 2024. New cuts will bring its workforce under 100. www.bizjournals.com/sanfrancisco...
This East Bay company had an IPO less than two years ago. Now it's laying off a quarter of its staff and installing a new CEO - San Francisco Business Times
Metagenomi will cut 31 jobs and shift focus to its hemophilia A gene therapy as founding CEO Brian Thomas steps down and Jian Irish takes over.
www.bizjournals.com
November 13, 2025 at 12:55 AM
The nine-year-old company, which IPO'd in February 2024, peaked at 237 employees in spring 2024. New cuts will bring its workforce under 100. www.bizjournals.com/sanfrancisco...
Reposted by Ron Leuty
I spoke to CNN about how demoralizing it was to watch Stanford leadership stay silent while contrarians on campus launched unscientific attacks to stifle Stanford researchers. Now, those attacks have gone nationwide and much of MAHA leadership have ties to Stanford.
www.cnn.com/2025/11/08/p...
www.cnn.com/2025/11/08/p...
The Trump-MAHA-Stanford nexus of US health policy | CNN Politics
In early 2022, Stanford medical student Santiago Sanchez set out to organize a campus debate with Jay Bhattacharya — a professor at the university whose outspoken denunciations of pandemic lockdowns m...
www.cnn.com
November 10, 2025 at 5:52 PM
I spoke to CNN about how demoralizing it was to watch Stanford leadership stay silent while contrarians on campus launched unscientific attacks to stifle Stanford researchers. Now, those attacks have gone nationwide and much of MAHA leadership have ties to Stanford.
www.cnn.com/2025/11/08/p...
www.cnn.com/2025/11/08/p...
"Our technology has the potential to truly enable the delivery of a breadth of siRNA therapeutic opportunities to all patient populations." www.bizjournals.com/sanfrancisco...
Codexis switches CEOs as it lays off workers and grabs manufacturing space in East Bay - San Francisco Business Times
Here's why a Peninsula biotech switched CEOs, cut jobs and took new space in Hayward.
www.bizjournals.com
November 10, 2025 at 11:06 PM
"Our technology has the potential to truly enable the delivery of a breadth of siRNA therapeutic opportunities to all patient populations." www.bizjournals.com/sanfrancisco...
Reposted by Ron Leuty
Step 1: Make things more expensive by taxing them
Step 2: Realize you're unpopular because of Step 1
Step 3: Use finances (illegally) obtained via taxes to buy support
Step 4: Drive up prices because you've subsidized taxed consumption
Step 2: Realize you're unpopular because of Step 1
Step 3: Use finances (illegally) obtained via taxes to buy support
Step 4: Drive up prices because you've subsidized taxed consumption
Trump: "We're gonna issue a dividend to our middle income people and lower income people of about $2,000, and we're gonna use the remaining tariffs to lower our debt."
November 10, 2025 at 9:05 PM
Step 1: Make things more expensive by taxing them
Step 2: Realize you're unpopular because of Step 1
Step 3: Use finances (illegally) obtained via taxes to buy support
Step 4: Drive up prices because you've subsidized taxed consumption
Step 2: Realize you're unpopular because of Step 1
Step 3: Use finances (illegally) obtained via taxes to buy support
Step 4: Drive up prices because you've subsidized taxed consumption
Adverum warned in August of its desperate need for cash. It turns out it was already was deep in talks with Lilly at that time, but on a licensing deal, not a buyout. Then a loan. www.bizjournals.com/sanfrancisco...
How Adverum and its pioneering gene therapy ended up in a buyout by drug giant Lilly - San Francisco Business Times
Here’s exactly how Adverum and its pioneering gene therapy ended up in an unusual deal with Lilly.
www.bizjournals.com
November 10, 2025 at 3:49 PM
Adverum warned in August of its desperate need for cash. It turns out it was already was deep in talks with Lilly at that time, but on a licensing deal, not a buyout. Then a loan. www.bizjournals.com/sanfrancisco...
Kezar Life Sciences to lay off 70% amid FDA setback - San Francisco Business Times www.bizjournals.com/sanfrancisco...
Kezar Life Sciences to lay off 70% of workforce as dispute with FDA apparently continues - San Francisco Business Times
Kezar Life Sciences to cut 70% of jobs in restructuring
www.bizjournals.com
November 10, 2025 at 3:43 PM
Kezar Life Sciences to lay off 70% amid FDA setback - San Francisco Business Times www.bizjournals.com/sanfrancisco...
Denali Therapeutics' Carole Ho leaves for Lilly neuroscience job - San Francisco Business Times www.bizjournals.com/sanfrancisco...
Denali Therapeutics is losing Carole Ho, as she heads to Lilly as head of neuroscience - San Francisco Business Times
Key Denali Therapeutics exec exits to head Lilly's neuroscience unit
www.bizjournals.com
November 7, 2025 at 12:15 AM
Denali Therapeutics' Carole Ho leaves for Lilly neuroscience job - San Francisco Business Times www.bizjournals.com/sanfrancisco...
'We jumped all over it': How drug maker Evommune seized on the federal shutdown to nail a $150 million IPO www.bizjournals.com/sanfrancisco...
'We jumped all over it': How drug maker Evommune took advantage of the federal shutdown to nail a $150 million IPO - San Francisco Business Times
For this Bay Area company, the government shutdown created an opportunity. "We jumped all over" the chance to go public, the CEO told the Business Times.
www.bizjournals.com
November 6, 2025 at 10:51 PM
'We jumped all over it': How drug maker Evommune seized on the federal shutdown to nail a $150 million IPO www.bizjournals.com/sanfrancisco...